-
ORAL, DISEASE-MODIFYING
SMALL MOLECULE
INHIBITORS OF PROTEIN
SELF-ASSOCIATION FOR
NEURODEGENERATION
About Oligomerix
Oligomerix, Inc., is a privately held clinical stage biotechnology company pioneering the development of disease-modifying, oral small molecule therapeutics targeting protein aggregation in Alzheimer’s disease and rare neurodegenerative diseases such as progressive supranuclear palsy (PSP).
Technology
Oligomerix’s lead candidate is a small molecule inhibitor of tau self-association that targets the beginning of the tau aggregation cascade and its progression.
Pipeline
Oligomerix’s platform includes our lead compound (OLX07010) and 2nd generation series of compounds.
